SESSION TITLE: Respiratory Infections Posters
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: Infections are common important cause of severe complications in sickle cell patients, a person may not know what brought severe pain named crisis but infection common trigger .The Pneumonia Severity Index and CURB-65 predict outcomes in community acquired pneumonia but have limitations. Procalcitonin, a biomarker of bacterial infection, may provide prognostic information in community-acquired pneumonia. Our objective is to describe if procalcitonin in community-acquired pneumonia may Provides prognostic information with the Pneumonia Severity Index and CURB-65 in sickle cell adult patients.
METHODS: In 20 sickle cell positive adult patient presenting with a clinical and radiographic diagnosis of community acquired pneumonia, all patients were scored using pneumonia score index PSI and CRUB-65 ,we measured procalcitonin level in all patients
RESULTS: twenty patients formed the study.12 female 60% and 8 males 40%with mean of age 46.00_+10.26 all patients were stratified with PSI , CRUB65 and sampled for procalcitonin level for PSI class I (3) patients 15%, class II (10) patients 50%,class III (3) patients 15%, class IV( one) patient 5% and class V( 3) patients 15%with mean of 2.55_+1.276 were CRUB65 0 (2) patients 10% 1 (eleven) patients 55% two (3) patients 15% ,three( 4 )patients 20%with mean of 1.45_+0.94 proclacitonin >0.25 are( 8) patients 40% and >0.50 are (12 )patients 60% with mean of 1.098_+1.346.
CONCLUSIONS: procalcitonin levels on admission predict the severity of community-acquired pneumonia in sickle cell patients with a similar prognostic accuracy as PSI and CRUB65 and use of procalcitonin as an adjunct to existing rules may offer additional prognostic information in high risk patients as sickle cell positive patients.
CLINICAL IMPLICATIONS: Diagnosis of CAP in Sickle cell patients
DISCLOSURE: The following authors have nothing to disclose: Sherif Alsayed, Samar Marzouk
No Product/Research Disclosure Information